Autolus Therapeutics PLC $ 15.95 0.51 (3.3%)
Volume:
112,818
Avg Vol (1m):
246,910
Market Cap $:
835.49 Mil
Enterprise Value $:
651.66 Mil
P/E (TTM):
0.00
P/B:
3.20
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 7.52 | ||
| Equity-to-Asset | 0.83 | ||
| Debt-to-Equity | 0.11 | ||
| Debt-to-EBITDA | -0.19 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 7.31 | ||
| Beneish M-Score | -2.77 | ||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -12344.79 | ||
| Net Margin % | -10518.19 | ||
| ROE % | -47.52 | ||
| ROA % | -40.34 | ||
| ROC (Joel Greenblatt) % | -287.95 | ||
| 3-Year Revenue Growth Rate | -8.2 | ||
| 3-Year EBITDA Growth Rate | -46.8 | ||
| 3-Year EPS without NRI Growth Rate | -115.9 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 3.2 | ||
| PS Ratio | 592.95 | ||
| EV-to-EBIT | -4.27 | ||
| EV-to-EBITDA | -4.41 | ||
| EV-to-Revenue | 527.66 | ||
| Current Ratio | 9.12 | ||
| Quick Ratio | 9.12 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -48.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 3.22 | ||
| Earnings Yield (Greenblatt) % | -23.4 |